Page last updated: 2024-11-12

hes1 protein, human

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

HES1 protein, human: RefSeq NM_005524 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16131047
MeSH IDM0210395

Synonyms (13)

Synonym
149348-15-2
hry protein, human
rat-hairy-like protein
hairy and enhancer of split 1, (drosophila), human
hesx1 protein
hairy and enhancer of split 1 hlh protein, human
hes-1 protein, human
hes1 protein, human
rhl protein
hes-1 factor
transcription factor hes-1, human
hairy protein, human
DTXSID10164243

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The goal of this study was to assess the tolerability profile, pharmacokinetic properties, and effects on pharmacodynamic markers (Aβ, trefoil factor family 3 protein, dual specificity phosphatase 6, and hairy and enhancer of split-1) of single, oral doses of avagacestat in healthy, young, male volunteers."( Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers.
Albright, CF; Berman, RM; Castaneda, L; Croop, R; Dockens, RC; Gu, H; Huang, SP; Li, H; Slemmon, R; Smith, C; Sverdlov, O; Tong, G; Wang, JS; Wong, O, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" Given the oncogenic effects of Notch2, we analyzed its gene dosage in 40 embryonal brain tumors, detecting an increased copy number in 15% of cases."( Notch1 and notch2 have opposite effects on embryonal brain tumor growth.
Ball, D; Brat, DJ; Eberhart, CG; Elhassan, I; Fan, X; Mikolaenko, I; Ni, X; Perry, A; Wang, Y, 2004
)
0.32
" Our results suggest that (1) multiple factors should be considered with attempting to identify molecular-based prognostic factors for pediatric T-ALL, and (2) depending on the NOTCH1 signaling status, modifications in the types or dosing of standard chemotherapy drugs for T-ALL, or combinations of agents capable of targeting NOTCH1, AKT and/or mTOR with standard chemotherapy agents may be warranted."( The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Chen, Q; Cherian, C; Devidas, M; Ge, Y; Haska, CL; Kugel Desmoulin, S; LaFiura, K; Larson Gedman, A; Linda, SB; Matherly, LH; Taub, JW, 2009
)
0.35
"This was a multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study in 8 healthy young men (age, 18-45 years) per dosing panel."( Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers.
Albright, CF; Berman, RM; Castaneda, L; Croop, R; Dockens, RC; Gu, H; Huang, SP; Li, H; Slemmon, R; Smith, C; Sverdlov, O; Tong, G; Wang, JS; Wong, O, 2012
)
0.38
" Inhibition of HES1 in vivo via conditional expression of a HES1-directed shRNA or JI130 dosing impaired FN-RMS tumor xenograft growth."( Identification and targeting of a HES1-YAP1-CDKN1C functional interaction in fusion-negative rhabdomyosarcoma.
Bentley, RC; Chen, PH; Chen, X; Cheng, C; Chi, JA; Kirsch, DG; Kovach, AR; Linardic, CM; Oristian, KM, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (600)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's19 (3.17)18.2507
2000's157 (26.17)29.6817
2010's357 (59.50)24.3611
2020's67 (11.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.90 (24.57)
Research Supply Index6.42 (2.92)
Research Growth Index5.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (1.15%)5.53%
Reviews38 (6.24%)6.00%
Case Studies9 (1.48%)4.05%
Observational1 (0.16%)0.25%
Other554 (90.97%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]